This transmission electron microscope image shows SARS-CoV-2 , the virus that...
This transmission electron microscope image shows SARS-CoV-2 , the virus that causes COVID-19, isolated from a patient in the US. Virus particles are shown emerging from the surface of cells cultured in the lab. The spikes on the outer edge of the virus particles give coronaviruses their name, crown-like.

Source: NIAID-RML

British Covid-19 study

The more symptoms, the longer the antibodies remain

Asymptomatic coronavirus sufferers appear to lose detectable antibodies sooner than people who have exhibited COVID-19 symptoms, according to one of the biggest studies of its kind in Britain published on Tuesday.

The findings by Imperial College London and market research firm Ipsos Mori also suggest the loss of antibodies was slower in 18-24 year-olds compared to those aged 75 and over. Overall, samples from hundreds of thousands of people across England between mid-June and late September showed the prevalence of virus antibodies fell by more than a quarter. The research, commissioned by the British government and published Tuesday by Imperial, indicates people's immune response to COVID-19 reduces over time following infection. James Bethell, a junior health minister, called it "a critical piece of research, helping us to understand the nature of COVID-19 antibodies over time".

But scientists involved cautioned that a great deal remains unknown about people's long-term antibody response to the virus. "It remains unclear what level of immunity antibodies provide, or for how long this immunity lasts," said Paul Elliott, of Imperial's School of Public Health. The study involved 365,000 randomly-selected adults administering at home three rounds of finger prick tests for coronavirus antibodies between June 20 and September 28.

This very large study has shown that the proportion of people with detectable antibodies is falling over time.

Helen Ward

The results showed the number of people with antibodies fell by 26.5 percent over the approximate three-month period. Scaled up to a nationwide level, it meant the proportion of the English population with antibodies dropped from 6.0 percent to 4.4 percent, according to the study. The decline coincided with the prevalence of the virus falling dramatically across England—and the rest of Britain—following a months-long national shutdown which was eased over the summer. However, the research found the number of health care workers testing positive for antibodies did not change over time, potentially reflecting repeated, or higher initial, exposure to the virus.

"This very large study has shown that the proportion of people with detectable antibodies is falling over time," said Helen Ward, one of the lead authors. "We don't yet know whether this will leave these people at risk of reinfection with the virus that causes COVID-19, but it is essential that everyone continues to follow guidance to reduce the risk to themselves and others."

Source: Imperial College London 

28.10.2020

More on the subject:
Read all latest stories

Related articles

Photo

Pandemic forecast modelling

Exploring the uncertainties in Covid-19 simulations

Computer modelling to forecast Covid-19 mortality contains significant uncertainty in its predictions, according to an international study led by researchers at University College London (UCL) and…

Photo

Peptide research

A 'fake handshake' to trick the coronavirus

Scientists have developed peptides that fit snugly into a groove on the SARS-CoV-2 Spike protein that it would normally use to access a host cell. These protein fragments effectively trick the virus…

Photo

Healthcare facilities analysed

Cutting Coronavirus air contamination in hospitals

Preventing air contamination in healthcare facilities is crucial to minimise the airborne spread of Covid-19 and its new strains. Universal masking, rigorous use of and safe disposal of PPE, plus…

Related products

Sarstedt – Low DNA Binding Micro Tubes

Research Use Only (RUO)

Sarstedt – Low DNA Binding Micro Tubes

SARSTEDT AG & CO. KG
Shimadzu – CLAM-2030

Research Use Only (RUO)

Shimadzu – CLAM-2030

Shimadzu Europa GmbH
Subscribe to Newsletter